Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 17, 2026
U.S. Bancorp (USB) Delivers +22% EPS Growth in Strong Q2 2026 Results

U.S. Bancorp (USB) Delivers +22% EPS Growth in Strong Q2 2026 Results

Key Takeaways

  • U.S. Bancorp reported diluted earnings per share of $1.35 for the second quarter of 2026, up 22% year-over-year and above consensus estimates.
  • Net revenue reached a record $7.71 billion, reflecting 10% year-over-year growth driven by higher net interest and noninterest income.
  • Net income attributable to U.S. Bancorp totaled $2.18 billion, supported by positive operating leverage and improved credit quality.
  • The bank completed the acquisition of BTIG, boosting capital markets revenue by 62% to $512 million.
  • Common equity tier 1 (CET1) capital ratio stood at 10.8%, demonstrating strong capital position.
  • Shares declined modestly in premarket trading following the release, with investors focusing on costs and future margin trends.

Putting the Earnings in Context

U.S. Bancorp’s second quarter 2026 results offer useful perspective on how one of the larger U.S. banks is navigating shifting interest rates, loan demand, and opportunities in fee-based businesses. The combination of solid revenue growth and an earnings beat underscores the advantages of a diversified model, including the recent push into capital markets. These quarterly updates help investors gauge trends in net interest margins, deposit flows, and credit performance, all of which can shape valuations and broader sector views.

The Q2 2026 Numbers in Detail

U.S. Bancorp posted second quarter 2026 net revenue of $7.712 billion, which came in ahead of analyst estimates that ranged from roughly $7.57 billion to $7.61 billion. Diluted earnings per share reached $1.35, beating consensus forecasts of $1.27 to $1.29 and representing a 22% increase from $1.11 in the same period a year earlier. Net income attributable to U.S. Bancorp was $2.177 billion, up nearly 20% year-over-year. Net interest income rose to $4.387 billion while noninterest income reached $3.325 billion. The efficiency ratio improved to 57.1%, and the bank delivered 400 basis points of positive operating leverage. Average loans grew to $405.5 billion and average deposits to $515.1 billion. The common equity tier 1 (CET1) capital ratio was 10.8%. The company also raised its full-year revenue outlook after the release. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

Following the July 16, 2026, release, U.S. Bancorp shares fell about 1% in premarket trading despite the earnings beat. Market participants appeared to focus on expense trends, the pace of net interest margin expansion, and updated guidance rather than the strong top-line results. Broader bank sector sentiment remained mixed amid ongoing macroeconomic uncertainty and interest rate expectations.

Forward Outlook and Key Factors to Monitor

Investors will watch U.S. Bancorp’s progress on integrating the BTIG acquisition and its contribution to fee income growth. Management raised full-year revenue guidance, signaling confidence in sustained momentum across business lines.

Net interest margin trends will remain a focal point as the interest rate environment evolves. Loan growth, particularly in commercial and consumer segments, and deposit stability will provide further clues on balance sheet health.

Credit quality metrics, including net charge-offs and allowance levels, warrant attention given the bank’s emphasis on improving performance. Expense management and efficiency gains could influence profitability in coming quarters.

Upcoming catalysts include third quarter 2026 results scheduled for October 15, 2026, along with any updates on capital return plans or regulatory developments affecting the banking sector.

Using AI Tools for Portfolio Insights

In my own research workflow, I sometimes turn to Tickeron’s AI Screener when I want to quickly filter for stocks or ETFs that match specific technical patterns, fundamentals, or volatility profiles. It lets me scan thousands of names with customizable criteria and surface ideas that align with the themes I’m already tracking from earnings reports like this one. The tool has helped me spot comparable names in the banking sector and understand relative strength without spending hours on manual screens.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: USB

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


USB's RSI Indicator recovers from oversold territory

The RSI Oscillator for USB moved out of oversold territory on September 25, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 21 of the 29 cases the stock moved higher. This puts the odds of a move higher at 72%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 39 of 62 cases where USB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.

Following a +1.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where USB advanced for three days, in 180 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.

USB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on USB as a result. In 56 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.

USB moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for USB crossed bearishly below the 50-day moving average on August 31, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where USB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.

The Aroon Indicator for USB entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 4 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.511) is normal, around the industry mean (1.321). P/E Ratio (11.733) is within average values for comparable stocks, (24.015). Projected Growth (PEG Ratio) (1.773) is also within normal values, averaging (1.186). Dividend Yield (0.035) settles around the average of (0.030) among similar stocks. P/S Ratio (3.141) is also within normal values, averaging (3.747).

The Tickeron Seasonality Score of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating fairly steady price growth. USB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. USB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 57, placing this stock worse than average.

Notable companies

The most notable companies in this group are Itau Unibanco Banco Holding SA (NYSE:ITUB), US Bancorp (NYSE:USB), PNC Financial Services Group (NYSE:PNC), Deutsche Bank Aktiengesellschaft (NYSE:DB), Banco Bradesco SA (NYSE:BBD), Huntington Bancshares (NASDAQ:HBAN), Regions Financial Corp (NYSE:RF), KeyCorp (NYSE:KEY).

Industry description

Regional banks have a smaller reach than major banks, and cater mostly to one region of a country, such as a state or within a group of states. They offer services often similar – albeit with some limitations/smaller scale – compared to major banks. Taking deposits, making loans, mortgages, leases, credit cards , fund management, insurance and investment banking. SunTrust Banks, State Street Corp., M&T Bank Corp. are some examples of U.S. regional banks.

Market Cap

The average market capitalization across the Regional Banks Industry is 6.12B. The market cap for tickers in the group ranges from 22.65 to 173.74B. DBSDF holds the highest valuation in this group at 173.74B. The lowest valued company is VLYPP at 22.65.

High and low price notable news

The average weekly price growth across all stocks in the Regional Banks Industry was 0%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 8%. INTR experienced the highest price growth at 30%, while SHFS experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Regional Banks Industry was 61%. For the same stocks of the Industry, the average monthly volume growth was 173% and the average quarterly volume growth was 48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 50
Price Growth Rating: 49
SMR Rating: 38
Profit Risk Rating: 57
Seasonality Score: 53 (-100 ... +100)
View a ticker or compare two or three
USB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a major bank

Industry RegionalBanks

Industry
Major Banks
Address
800 Nicollet Mall
Phone
+1 651 466-3000
Employees
68520
Web
https://www.usbank.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.